We’re In The News

As a respected nonprofit health research center, our views are often quoted in the media, including newspapers, magazines, TV, radio, and websites. We also write articles and blogs for a number of different and highly respected newspapers, magazines, and popular websites, and we are published in prestigious medical journals and health policy publications. We frequently express our policy views in letters to government officials and public comments to federal agencies and we sometimes release statements or press releases on newsworthy issues.

Please e-mail info@center4research.org or call 202-223-4000 with your inquiries. We can assist you with scheduling interviews with the NCHR President, Dr. Diana Zuckerman, and other experts on our staff.

Bamboozled: Action in NJ to Ban ‘A Clear and Present Danger’ to Babies

NJ.com, October 20, 2016. A host of consumer safety and public health organizations have called for stronger action on dangerous supplemental mattresses, including NCHR.

With Overactive Bladder, Drug Companies Helped Create $3 Billion Market

MedPage Today, Milwaukee Journal Sentinel, October 15, 2016. Diana Zuckerman, president of the National Center for Health Research noted there is another factor arguing against the use of drugs to treat overactive bladder. “All of these drugs have the potential for serious risk,” she said. “So what’s the actual benefit? To weigh that against risks that can be serious, it’s pretty unimpressive.”

Anthem Says Will Not Cover Sarepta’s Approved Duchenne Drug

Reuters, October 7, 2016. To keep health insurance affordable, companies need to ensure that they are paying for safe and effective treatments, said Diana Zuckerman, president of non-profit organization National Center for Health Research. “When FDA fails to ensure those standards, then ‘FDA approval’ is no longer a gold standard that insurance companies can rely on,” she said.

Anthem Declines to Cover Sarepta Drug for Duchenne, Citing Doubts over Data

STAT News, October 7, 2016. One of the nation’s largest health insurers has decided not to cover a controversial Duchenne muscular dystrophy drug because its FDA approval was not based on scientific evidence that it works. This is what NCHR predicted would happen.

Obama Extends Controversial Program for Rare Pediatric Drugs

STAT News, September 30, 2016. Friday, President Barack Obama signed into law a bill that will briefly extend a voucher program that rewards drug makers for rare pediatric medicines.